CYP19A1 and breast cancer: According to recent data, about 70–80% of all BC patients undergo adjuvant endocrine therapy for at least 5 years [135], and there is evidence that fragility fractures occur within less than 5 years of being started on aromatase inhibitors, illustrating the rapid progression of bone loss [136], as confirmed by a recent meta-analysis study [60].